Evidence map›Paper›PMID 21830153›Full record

ArticleRheumatology international2012

Analysis of granulysin-mediated cytotoxicity in peripheral blood of patients with psoriatic arthritis.

Drazen Massari, Larisa Prpic-Massari, Tatjana Kehler, Marija Kastelan, Bozidar Curkovic, Viktor Persic, Alen Ruzic, Gordana Laskarin

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03469219 (Serum Granulysin as a Possible Key Marker to Detect the Severity of Psoriasis), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03469219 unknown statusnot on this mapstarted 2018, after this paper: background citation

Serum Granulysin as a Possible Key Marker to Detect the Severity of Psoriasis

TypeobservationalSponsorAssiut UniversityRan2018 to 2019Enrolled45ConditionsPsoriasis Vulgaris
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Increased granulysin in the peripheral blood and tissues of patients with oral lichen planus.International journal of clinical and experimental pathology · 2019
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Drazen MassariThalassotherapia Opatija, Special Hospital for Rehabilitation of Hearth and Lung Diseases and Rheumatism, M. Tita 188, 51410 Opatija, Croatia.
Larisa Prpic-Massari
Tatjana Kehler
Marija Kastelan
Bozidar Curkovic
Viktor Persic
Alen Ruzic
Gordana Laskarin
University of Rijeka · HRUniversity Hospital Centre Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of the present study was to investigate possible changes in granulysin (GNLY)-mediated cytotoxicity of peripheral blood lymphocytes in psoriatic arthritis (PsA) patients with respect to different phases of the disease. We prospectively enrolled 25 PsA patients in the active phase, 26 PsA patients in remission and 24 healthy controls. The simultaneous detection of intracellular GNLY and cell surface antigens (CD3 and CD56) was performed with flow cytometry. GNLY apoptotic protein was visualised by immunocytochemistry. Natural killer (NK) cell cytotoxicity was analysed with a cytotoxicity assay against human erythroleukaemia K-562 cells. The percentage of GNLY(+) cells did not differ significantly between PsA patients in the acute phase and those in remission; however, it was always higher than in healthy examinees due to the increased percentage of GNLY(+) cells within T cells, NKT cells, and both, and in the CD56(+dim) and CD56(+bright) NK subsets. The mean fluorescence intensity for GNLY was higher in all lymphocyte subpopulations in the acute phase than in remission and in healthy controls. Accordingly, GNLY-mediated NK cell cytotoxicity against K-562 cells of active phase PsA patients was significantly higher than that in patients in remission or in healthy controls. These findings demonstrated the involvement of GNLY in the worsening of PsA and suggested that GNLY mediated the development of joint lesions.

Indexed as

Antigens, Differentiation, T-LymphocyteAntirheumatic AgentsApoptosisArthritis, PsoriaticCase-Control StudiesCD3 ComplexCD56 AntigenCell Line, TumorCytotoxicity, ImmunologicFemaleHumansKiller Cells, NaturalLeukemia, Erythroblastic, AcuteMaleMiddle AgedProspective StudiesAntigens, Differentiation, T-LymphocyteAntirheumatic AgentsCD3 ComplexCD56 AntigenGNLY protein, human

Identifiers

PMID21830153
OpenAlexW1996881926

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.